What is HC Wainwright’s Estimate for WVE Q1 Earnings?

WAVE Life Sciences Ltd. (NASDAQ:WVE) – Research analysts at HC Wainwright issued their Q1 2026 EPS estimates for WAVE Life Sciences in a research note issued on Friday, December 19th. HC Wainwright analyst A. Fein anticipates that the company will post earnings of ($0.35) per share for the quarter. HC Wainwright has a “Buy” rating and a $30.00 price objective on the stock. The consensus estimate for WAVE Life Sciences’ current full-year earnings is ($1.14) per share. HC Wainwright also issued estimates for WAVE Life Sciences’ Q2 2026 earnings at ($0.35) EPS and Q4 2026 earnings at ($0.34) EPS.

WAVE Life Sciences (NASDAQ:WVE) last issued its earnings results on Monday, November 10th. The company reported ($0.32) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.30) by ($0.02). WAVE Life Sciences had a negative net margin of 111.64% and a negative return on equity of 75.61%. The business had revenue of $7.61 million during the quarter, compared to analyst estimates of $9.85 million.

A number of other equities research analysts also recently weighed in on WVE. Raymond James Financial restated an “outperform” rating and issued a $21.00 price target on shares of WAVE Life Sciences in a research note on Monday, December 8th. Wall Street Zen raised shares of WAVE Life Sciences from a “sell” rating to a “hold” rating in a research note on Saturday, December 13th. Truist Financial boosted their target price on shares of WAVE Life Sciences from $36.00 to $50.00 and gave the stock a “buy” rating in a research note on Monday, December 15th. B. Riley upped their price target on shares of WAVE Life Sciences from $19.00 to $37.00 and gave the stock a “buy” rating in a report on Friday, December 12th. Finally, Oppenheimer increased their price target on WAVE Life Sciences from $24.00 to $32.00 and gave the company an “outperform” rating in a research note on Tuesday, December 16th. Thirteen analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, WAVE Life Sciences has a consensus rating of “Moderate Buy” and a consensus target price of $31.67.

WAVE Life Sciences Stock Down 2.7%

WAVE Life Sciences stock opened at $17.48 on Monday. WAVE Life Sciences has a 12-month low of $5.28 and a 12-month high of $21.73. The business’s 50-day moving average price is $9.91 and its two-hundred day moving average price is $8.55. The stock has a market cap of $2.92 billion, a PE ratio of -23.31 and a beta of -1.72.

Insider Transactions at WAVE Life Sciences

In other news, Director Christian O. Henry sold 93,445 shares of the stock in a transaction on Monday, December 8th. The shares were sold at an average price of $14.65, for a total transaction of $1,368,969.25. Following the completion of the sale, the director directly owned 12,700 shares in the company, valued at $186,055. This represents a 88.04% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, major shareholder Plc Gsk bought 1,470,000 shares of the stock in a transaction that occurred on Thursday, December 11th. The shares were purchased at an average cost of $19.00 per share, with a total value of $27,930,000.00. Following the purchase, the insider directly owned 18,245,691 shares of the company’s stock, valued at $346,668,129. The trade was a 8.76% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. In the last ninety days, insiders have sold 902,742 shares of company stock worth $13,313,763. Company insiders own 23.98% of the company’s stock.

Institutional Investors Weigh In On WAVE Life Sciences

Large investors have recently bought and sold shares of the stock. CIBC Bancorp USA Inc. acquired a new position in shares of WAVE Life Sciences during the third quarter valued at about $87,000. Polar Capital Holdings Plc increased its position in WAVE Life Sciences by 5.9% in the 3rd quarter. Polar Capital Holdings Plc now owns 1,062,276 shares of the company’s stock valued at $7,776,000 after buying an additional 58,776 shares in the last quarter. HighVista Strategies LLC increased its position in WAVE Life Sciences by 64.8% in the 3rd quarter. HighVista Strategies LLC now owns 59,261 shares of the company’s stock valued at $434,000 after buying an additional 23,303 shares in the last quarter. Bank of America Corp DE raised its stake in WAVE Life Sciences by 3.0% during the 3rd quarter. Bank of America Corp DE now owns 665,150 shares of the company’s stock worth $4,869,000 after buying an additional 19,590 shares during the period. Finally, Ameriprise Financial Inc. bought a new position in WAVE Life Sciences in the third quarter worth approximately $790,000. 89.73% of the stock is currently owned by institutional investors and hedge funds.

About WAVE Life Sciences

WAVE Life Sciences is a clinical-stage genetic medicines company focused on the discovery and development of stereopure oligonucleotide therapies designed to address serious diseases with high unmet medical need. Leveraging proprietary chemistry and precision synthesis, WAVE engineers drug candidates with defined stereochemistry to optimize potency, safety and manufacturability. This approach aims to enhance target specificity and improve therapeutic profiles compared with traditional oligonucleotide medicines.

The company’s pipeline includes programs in neuromuscular disorders such as Duchenne muscular dystrophy and neurodegenerative conditions including Huntington’s disease, as well as early-stage cardiovascular and liver indications.